The anti-
cancer agent,
cyclophosphamide, metabolises to the cytotoxic
alkylating agent phosphoramide mustard, which can be dephosphoramidated to give
nornitrogen mustard. A rat liver mitochondrial supernatant system was used to study the binding of [chloroethyl 3H]
cyclophosphamide to
DNA. The reacted
DNA was
acid-hydrolysed and one major adduct was identified using
Sephadex G-10 chromatography, followed by HPLC, using reversed-phase or ion-exchange systems. Further studies, using [14C]
guanine as reaction substrate for [chloroethyl 3H]
cyclophosphamide,
phosphoramide mustard or
nornitrogen mustard, demonstrated the main adduct from each reaction had identical chromatographic properties in these systems. The radiolabelled ratio in the [3H]
cyclophosphamide-[14C]
guanine reaction demonstrated a monoadducted product. From this evidence and from 1H NMR data, the common adduct was putatively identified as a hydroxylated
nornitrogen mustard adduct (N-(2-hydroxyethyl)-N-[2-(7-guaninyl)ethyl]
amine). In in vivo studies, rats were injected intraperitoneally with 2.775 MBq [3H]
cyclophosphamide. Total organ [3H] content and
DNA binding levels were ascertained. Maximal levels of [3H] binding to
DNA were seen between 1-4 hr with the highest binding levels observed in the bladder. The in vivo adduct was shown, using various HPLC systems, to co-chromatograph with the in vitro adduct and thus the main in vivo adduct was putatively identified as N-(2-hydroxyethyl)-N-[2-(7-guaninyl)ethyl]
amine.